IL17A and psoriasis: Although combination therapies with anti-IL-17 biologics are less studied, there is one report including 4 patients with recalcitrant psoriasis who achieved a PASI 75 reduction after treatment for 6–9 months with Secukinumab and Apremilast (phosphodiesterase-4 inhibitor) [49].